Armistice Capital reports 3.74M shares (4.23%) of Kura

Armistice Capital, LLC and Steven Boyd filed Amendment No. 5 to a Schedule 13G/A reporting shared beneficial ownership of 3,736,000 shares of Kura Oncology common stock, equal to 4.23% (03/31/2026).

Rhea-AI Filing Summary

Armistice Capital, LLC and Steven Boyd filed Amendment No. 5 to a Schedule 13G/A reporting shared beneficial ownership of 3,736,000 shares of Kura Oncology common stock, equal to 4.23% (03/31/2026). The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that the Master Fund disclaims beneficial ownership by reason of its Investment Management Agreement with Armistice Capital.

Insights

Institutional Ownership Specialist

Armistice reports a passive, sub-5% stake via its managed Master Fund.

The filing lists 3,736,000 shares representing 4.23% of Kura Oncology as of 03/31/2026, held directly by Armistice Capital Master Fund Ltd., with Armistice Capital exercising voting and investment power under an Investment Management Agreement.

Because the position is under 5% and described under a manager/client structure, regulatory disclosure is routine; subsequent amendments or larger stake changes would be the primary items to watch in future filings.

Corporate Governance Analyst

Shared voting and dispositive power is disclosed; the Master Fund disclaims direct beneficial ownership.

The Schedule 13G/A shows shared voting power and shared dispositive power of 3,736,000 shares, with zero sole power reported. The filing attributes those powers to Armistice as investment manager and to Steven Boyd as managing member.

Governance implications hinge on whether the holder moves above 5% or changes intentions; for now, the filing documents passive reporting and manager-client attribution.

Key Figures

Shares beneficially owned: 3,736,000 shares Percent of class: 4.23% CUSIP: 50127T109

3 metrics

Shares beneficially owned 3,736,000 shares Amount reported in Item 4(a)

Percent of class 4.23% Percent reported in Item 4(b); reporting date <date>03/31/2026</date>

CUSIP 50127T109 Identifier for Kura Oncology common stock on cover

Key Terms

Investment Management Agreement, beneficially owned, shared dispositive power

3 terms

Investment Management Agreement regulatory

"Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd."

An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.

beneficially owned financial

"Amount beneficially owned: 3,736,000"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power regulatory

"Shared Dispositive Power 3,736,000.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Armistice Capital report in KURA?

Armistice Capital reports beneficial ownership of 3,736,000 shares, equal to 4.23%. This position is held directly by Armistice Capital Master Fund Ltd., with Armistice Capital exercising voting and investment power under an Investment Management Agreement.

Who is the direct holder of the shares reported by Armistice Capital?

The direct holder is Armistice Capital Master Fund Ltd. The filing states the Master Fund holds the shares while Armistice Capital, as manager, exercises voting and investment power over those securities.

Does the filing show sole voting or dispositive power?

No; the filing shows 0 sole voting power and 0 sole dispositive power, and discloses 3,736,000 shared voting and dispositive powers held through the manager-client relationship.

When is the ownership position reported as of?

The Schedule 13G/A lists the reporting date as 03/31/2026 and signatures dated 05/15/2026, indicating the position count is presented with that reporting period in the amendment.

Does the Master Fund claim beneficial ownership in the filing?

The Master Fund explicitly disclaims beneficial ownership in the filing because it states it lacks the power to vote or dispose of the securities due to its Investment Management Agreement with Armistice Capital.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 11:26 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

KURA ONCOLOGY, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

50127T109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 50127T109

1

Names of Reporting Persons

Armistice Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,736,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,736,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,736,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.23 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP Number(s): 50127T109

1

Names of Reporting Persons

Steven Boyd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,736,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,736,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,736,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.23 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KURA ONCOLOGY, INC.
(b)	Address of issuer's principal executive offices: 4930 Directors Place, Suite 500, San Diego, CA 92121
Item 2.
(a)	Name of person filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b)	Address or principal business office or, if none, residence: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c)	Citizenship: Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 50127T109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,736,000
(b)	Percent of class: 4.23%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,736,000
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,736,000 Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Armistice Capital, LLC

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd - Managing Member
Date:	05/15/2026

Steven Boyd

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd
Date:	05/15/2026

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd